614 research outputs found

    Π‘ΠΈΠ½Ρ‚Π΅Π· Ρ‚Π° Π΄Ρ–ΡƒΡ€Π΅Ρ‚ΠΈΡ‡Π½Π° дія 8-Π°ΠΌΡ–Π½ΠΎΠ·Π°ΠΌΡ–Ρ‰Π΅Π½ΠΈΡ… 7-(2-гідрокси-3-ΠΏ-мСтоксифСноксипропіл-1)-3-мСтилксантину

    Get PDF
    It has been found that natural xanthines, as well as their synthetic analogs, possess the diuretic effect. Analysis of the literature proves that there is a great opportunity of applying synthetic derivatives of N-methylated xanthines as potential diuretics.Aim. To develop preparative methods of the synthesis of 8-aminosubstituted of 7-(2-hydroxy-3-p-metoxyphenoxypropyl-1)-3-methylxanthine and study their physical, chemical and biological properties. Results. The synthesis of a series of 8-aminosubstituted of 7-(2-hydroxy-3-p-metoxyphenoxypropyl-1)-3-methylxanthine was carried out. According to the results of the biological testing the compounds synthesized belong to the toxicity of class IV. 7-(2-Hydroxy-3-p-methoxyphenoxypropyl-1)-8-(furyl-2-methylamino)-3-methylxanthine xanthine shows the highest diuretic activity, and hence, requires a more in-depth study since it is twice more active than hydrochlorothiazide. It should be emphasized that all compounds synthesized exhibit a marked diuretic effect. Experimental part. 8-Bromo-7-(2-hydroxy-3-p-methoxyphenoxypropyl-1)-3-methylxanthine was obtained by heating 8-bromo-3-methylxanthine with p-methoxyphenoxymethyloxirane in butanol-1 and in the presence of N,N-dimethylbenzylamine. 8-Aminosubstitutied of 7-(2-hydroxy-3-p-metoxyphenoxypropyl-1)-3-methylxanthine was obtained by boiling of bromoalcohol with the primary and secondary amines. The structure of the compounds synthesized was unambiguously confirmed by NMR-spectroscopy. The acute toxicity of the compounds obtained was studied by Kerber method. The study of the diuretic activity of the compounds was carried out using Ye. Berkhin method. Hydrochlorothiazide was used as a reference substance. Conclusions. Simple methods for the synthesis of 8-amino-7- (2-hydroxy-3-p-methoxyphenoxypropyl-1)-3-methylxanthines have been developed. The structure of the compounds synthesized has been confirmed by the method of NMR 1H-spectroscopy. The acute toxicity and the diuretic activity of the compounds obtained have been studied.Π˜Π·Π²Π΅ΡΡ‚Π½ΠΎ, Ρ‡Ρ‚ΠΎ ΠΊΠ°ΠΊ ΠΏΡ€ΠΈΡ€ΠΎΠ΄Π½Ρ‹Π΅ ксантины, Ρ‚Π°ΠΊ ΠΈ ΠΈΡ… синтСтичСскиС Π°Π½Π°Π»ΠΎΠ³ΠΈ ΠΎΠ±Π»Π°Π΄Π°ΡŽΡ‚ диурСтичСским дСйствиСм. Анализ Π΄Π°Π½Π½Ρ‹Ρ… Π»ΠΈΡ‚Π΅Ρ€Π°Ρ‚ΡƒΡ€Ρ‹ ΡΠ²ΠΈΠ΄Π΅Ρ‚Π΅Π»ΡŒΡΡ‚Π²ΡƒΠ΅Ρ‚ ΠΎ Π·Π½Π°Ρ‡ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠΉ пСрспСктивС использования синтСтичСских ΠΏΡ€ΠΎΠΈΠ·Π²ΠΎΠ΄Π½Ρ‹Ρ… N-ΠΌΠ΅Ρ‚ΠΈΠ»ΠΈΡ€ΠΎΠ²Π°Π½Π½Ρ‹Ρ… ксантинов Π² качСствС ΠΏΠΎΡ‚Π΅Π½Ρ†ΠΈΠ°Π»ΡŒΠ½Ρ‹Ρ… диурСтичСских срСдств. ЦСль Π΄Π°Π½Π½ΠΎΠΉ Ρ€Π°Π±ΠΎΡ‚Ρ‹ – Ρ€Π°Π·Ρ€Π°Π±ΠΎΡ‚ΠΊΠ° ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚ΠΈΠ²Π½Ρ‹Ρ… ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠ² синтСза 8-Π°ΠΌΠΈΠ½ΠΎΠ·Π°ΠΌΠ΅Ρ‰Π΅Π½Π½Ρ‹Ρ… 7-(2-гидрокси-3-ΠΏ-мСтоксифСноксипропил-1)-3-мСтилксантина ΠΈ ΠΈΠ·ΡƒΡ‡Π΅Π½ΠΈΠ΅ ΠΈΡ… Ρ„ΠΈΠ·ΠΈΠΊΠΎ-химичСских ΠΈ биологичСских свойств. Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ ΠΈ ΠΈΡ… обсуТдСниС. Π‘ΠΈΠ½Ρ‚Π΅Π·ΠΈΡ€ΠΎΠ²Π°Π½ ряд 8-Π°ΠΌΠΈΠ½ΠΎΠ·Π°ΠΌΠ΅Ρ‰Π΅Π½Π½Ρ‹Ρ… 7-(2-гидрокси-3-ΠΏ-мСтоксифСноксипропил-1)-3-мСтилксантина. По Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Π°ΠΌ биологичСских испытаний синтСзированныС соСдинСния относятся ΠΊ IV классу токсичности. 7-(2-Гидрокси-3-ΠΏ-мСтоксифСноксипропил-1)-8-(Ρ„ΡƒΡ€ΠΈΠ»-2-ΠΌΠ΅Ρ‚ΠΈΠ»Π°ΠΌΠΈΠ½ΠΎ)-3-мСтилксантин ΠΈΠΌΠ΅Π΅Ρ‚ Π½Π°ΠΈΠ±ΠΎΠ»ΡŒΡˆΡƒΡŽ Π΄ΠΈΡƒΡ€Π΅Ρ‚ΠΈΡ‡Π΅ΡΠΊΡƒΡŽ Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ, Π° ΡΠ»Π΅Π΄ΠΎΠ²Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎ Π½Π΅ΠΎΠ±Ρ…ΠΎΠ΄ΠΈΠΌΠΎ доскональноС ΠΈΠ·ΡƒΡ‡Π΅Π½ΠΈΠ΅, ΠΏΠΎΡΠΊΠΎΠ»ΡŒΠΊΡƒ ΠΎΠ½ Π±ΠΎΠ»Π΅Π΅ Ρ‡Π΅ΠΌ Π² 2 Ρ€Π°Π·Π° Π°ΠΊΡ‚ΠΈΠ²Π½Π΅Π΅Β  Π³ΠΈΠ΄Ρ€ΠΎΡ…Π»ΠΎΡ€Ρ‚ΠΈΠ°Π·ΠΈΠ΄Π°. НСобходимо ΠΏΠΎΠ΄Ρ‡Π΅Ρ€ΠΊΠ½ΡƒΡ‚ΡŒ, Ρ‡Ρ‚ΠΎ всС синтСзированныС соСдинСния ΠΎΠΊΠ°Π·Ρ‹Π²Π°ΡŽΡ‚ Π²Ρ‹Ρ€Π°ΠΆΠ΅Π½Π½ΠΎΠ΅ диурСтичСскоС дСйствиС. Π­ΠΊΡΠΏΠ΅Ρ€ΠΈΠΌΠ΅Π½Ρ‚Π°Π»ΡŒΠ½Π°Ρ Ρ‡Π°ΡΡ‚ΡŒ. 8-Π‘Ρ€ΠΎΠΌ-7-(2-гидрокси-3-ΠΏ-мСтоксифСнокси­пропил-1)-3-мСтилксантин ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½ Π½Π°Π³Ρ€Π΅Π²Π°Π½ΠΈΠ΅ΠΌ 8-Π±Ρ€ΠΎΠΌ-3-мСтилксантина с ΠΏ-мСтоксифСноксимСтилоксираном Π² Π±ΡƒΡ‚Π°Π½ΠΎΠ»Π΅-1 Π² присутствии N,N-Π΄ΠΈΠΌΠ΅Ρ‚ΠΈΠ»Π±Π΅Π½Π·ΠΈΠ»Π°ΠΌΠΈΠ½Π°. 8-АминозамСщСнныС 7-(2-гидрокси-3-ΠΏ-мСтокси­фСноксипропил-1)-3-мСтилксантина синтСзированы ΠΏΡƒΡ‚Π΅ΠΌ кипячСния бромоспирта с ΠΏΠ΅Ρ€Π²ΠΈΡ‡Π½Ρ‹ΠΌΠΈ ΠΈ Π²Ρ‚ΠΎΡ€ΠΈΡ‡Π½Ρ‹ΠΌΠΈ Π°ΠΌΠΈΠ½Π°ΠΌΠΈ. Π‘Ρ‚Ρ€ΡƒΠΊΡ‚ΡƒΡ€Π° синтСзированных соСдинСний ΠΎΠ΄Π½ΠΎΠ·Π½Π°Ρ‡Π½ΠΎ Π΄ΠΎΠΊΠ°Π·Π°Π½Π° ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ ПМР-спСктроскопии. ΠžΡΡ‚Ρ€Π°Ρ Ρ‚ΠΎΠΊΡΠΈΡ‡Π½ΠΎΡΡ‚ΡŒ синтСзированных соСдинСний ΠΈΠ·ΡƒΡ‡Π°Π»Π°ΡΡŒ ΠΏΠΎ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρƒ ΠšΠ΅Ρ€Π±Π΅Ρ€Π°. Π˜Π·ΡƒΡ‡Π΅Π½ΠΈΠ΅ диурСтичСской активности ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½Π½Ρ‹Ρ… соСдинСний ΠΏΡ€ΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΠΏΠΎ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρƒ Π‘Π΅Ρ€Ρ…ΠΈΠ½Π° Π•. Π‘. Π’ качСствС эталона сравнСния использовали Π³ΠΈΠ΄Ρ€ΠΎΡ…Π»ΠΎΡ€Ρ‚ΠΈΠ°Π·ΠΈΠ΄. Π’Ρ‹Π²ΠΎΠ΄Ρ‹. Π Π°Π·Ρ€Π°Π±ΠΎΡ‚Π°Π½Ρ‹ простыС Π² Π²Ρ‹ΠΏΠΎΠ»Π½Π΅Π½ΠΈΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΈΠΊΠΈ синтСза 8-Π°ΠΌΠΈΠ½ΠΎΠ·Π°ΠΌΠ΅Ρ‰Π΅Π½Π½Ρ‹Ρ… 7-(2-гидрокси-3-ΠΏ-мСтоксифСноксипропил-1)-3-мСтилксантина. Π‘Ρ‚Ρ€ΡƒΠΊΡ‚ΡƒΡ€Π° синтСзированных соСдинСний Π΄ΠΎΠΊΠ°Π·Π°Π½Π° ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ ПМР-спСктроскопии. Π˜Π·ΡƒΡ‡Π΅Π½Π° острая Ρ‚ΠΎΠΊΡΠΈΡ‡Π½ΠΎΡΡ‚ΡŒ ΠΈ диурСтичСская Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½Π½Ρ‹Ρ… вСщСств.Π’Ρ–Π΄ΠΎΠΌΠΎ, Ρ‰ΠΎ як ΠΏΡ€ΠΈΡ€ΠΎΠ΄Π½Ρ– ксантини, Ρ‚Π°ΠΊ Ρ– Ρ—Ρ… синтСтичні Π°Π½Π°Π»ΠΎΠ³ΠΈ Π²ΠΈΡΠ²Π»ΡΡŽΡ‚ΡŒ Π΄Ρ–ΡƒΡ€Π΅Ρ‚ΠΈΡ‡Π½Ρƒ Π΄Ρ–ΡŽ. Аналіз Π΄Π°Π½ΠΈΡ… Π»Ρ–Ρ‚Π΅Ρ€Π°Ρ‚ΡƒΡ€ΠΈ ΡΠ²Ρ–Π΄Ρ‡ΠΈΡ‚ΡŒ ΠΏΡ€ΠΎ Π·Π½Π°Ρ‡Π½Ρƒ пСрспСктиву використання синтСтичних ΠΏΠΎΡ…Ρ–Π΄Π½ΠΈΡ… N-ΠΌΠ΅Ρ‚ΠΈΠ»ΡŒΠΎΠ²Π°Π½ΠΈΡ… ксантинів Π² якості ΠΏΠΎΡ‚Π΅Π½Ρ†Ρ–ΠΉΠ½ΠΈΡ… Π΄Ρ–ΡƒΡ€Π΅Ρ‚ΠΈΡ‡Π½ΠΈΡ… засобів. ΠœΠ΅Ρ‚ΠΎΡŽ Π΄Π°Π½ΠΎΡ— Ρ€ΠΎΠ±ΠΎΡ‚ΠΈ Ρ” Ρ€ΠΎΠ·Ρ€ΠΎΠ±ΠΊΠ° ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚ΠΈΠ²Π½ΠΈΡ… ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ–Π² синтСзу 8-Π°ΠΌΡ–Π½ΠΎΠ·Π°ΠΌΡ–Ρ‰Π΅Π½ΠΈΡ… 7-(2-гідрокси-3-ΠΏ-мСтоксифСноксипропіл-1)-3-мСтилксантину Ρ‚Π° вивчСння Ρ—Ρ… Ρ„Ρ–Π·ΠΈΠΊΠΎ-Ρ…Ρ–ΠΌΡ–Ρ‡Π½ΠΈΡ… Ρ‚Π° Π±Ρ–ΠΎΠ»ΠΎΠ³Ρ–Ρ‡Π½ΠΈΡ… властивостСй. Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚ΠΈ Ρ‚Π° Ρ—Ρ… обговорСння. Π‘ΡƒΠ² синтСзований ряд 8-Π°ΠΌΡ–Π½ΠΎΠ·Π°ΠΌΡ–Ρ‰Π΅Π½ΠΈΡ… 7-(2-гідрокси-3-ΠΏ-мСтоксифСноксипропіл-1)-3-мСтилксантину. Π—Π° Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Π°ΠΌΠΈ Π±Ρ–ΠΎΠ»ΠΎΠ³Ρ–Ρ‡Π½ΠΈΡ… Π²ΠΈΠΏΡ€ΠΎΠ±ΡƒΠ²Π°Π½ΡŒ синтСзовані сполуки Π²Ρ–Π΄Π½ΠΎΡΡΡ‚ΡŒΡΡ Π΄ΠΎ IV класу токсичності. 7-(2-Гідрокси-3-ΠΏ-мСтоксифСноксипропіл-1)-8-(Ρ„ΡƒΡ€ΠΈΠ»-2-ΠΌΠ΅Ρ‚ΠΈΠ»Π°ΠΌΡ–Π½ΠΎ)-3-мСтилксантин виявляє Π½Π°ΠΉΠ²ΠΈΡ‰Ρƒ Π΄Ρ–ΡƒΡ€Π΅Ρ‚ΠΈΡ‡Π½Ρƒ Π°ΠΊΡ‚ΠΈΠ²Π½Ρ–ΡΡ‚ΡŒ, Π° ΠΎΡ‚ΠΆΠ΅ ΠΏΠΎΡ‚Ρ€Π΅Π±ΡƒΡ” Π±Ρ–Π»ΡŒΡˆ досконалого вивчСння, ΠΎΡΠΊΡ–Π»ΡŒΠΊΠΈ Π²Ρ–Π½ Π±Ρ–Π»ΡŒΡˆ Π½Ρ–ΠΆ Ρƒ 2 Ρ€Π°Π·ΠΈ Π°ΠΊΡ‚ΠΈΠ²Π½Ρ–ΡˆΠΈΠΉ Π·Π° Π³Ρ–Π΄Ρ€ΠΎΡ…Π»ΠΎΡ€Ρ‚Ρ–Π°Π·ΠΈΠ΄. НСобхідно підкрСслити, Ρ‰ΠΎ всі синтСзовані сполуки Π²ΠΈΡΠ²Π»ΡΡŽΡ‚ΡŒ Π²ΠΈΡ€Π°Π·Π½Ρƒ Π΄Ρ–ΡƒΡ€Π΅Ρ‚ΠΈΡ‡Π½Ρƒ Π΄Ρ–ΡŽ.Π•ΠΊΡΠΏΠ΅Ρ€ΠΈΠΌΠ΅Π½Ρ‚Π°Π»ΡŒΠ½Π° частина. 8-Π‘Ρ€ΠΎΠΌΠΎ-7-(2-гідрокси-3-ΠΏ-мСтоксифСноксипропіл-1)-3-мСтилксантин ΠΎΡ‚Ρ€ΠΈΠΌΠ°Π»ΠΈ нагріванням 8-Π±Ρ€ΠΎΠΌΠΎ-3-мСтилксантину Π· ΠΏ-мСтоксифСноксимСтилоксираном Ρƒ Π±ΡƒΡ‚Π°Π½ΠΎΠ»Ρ–-1 Π² присутності N,N-Π΄ΠΈΠΌΠ΅Ρ‚ΠΈΠ»Π±Π΅Π½Π·ΠΈΠ»Π°ΠΌΡ–Π½Ρƒ. 8-АмінозаміщСні 7-(2-гідрокси-3-ΠΏ-мСтоксифСноксипропіл-1)-3-мСтилксантину синтСзовані ΡˆΠ»ΡΡ…ΠΎΠΌ кип’ятіння бромоспирту Π· ΠΏΠ΅Ρ€Π²ΠΈΠ½Π½ΠΈΠΌΠΈ Ρ‚Π° Π²Ρ‚ΠΎΡ€ΠΈΠ½Π½ΠΈΠΌΠΈ Π°ΠΌΡ–Π½Π°ΠΌΠΈ. Π‘Ρ‚Ρ€ΡƒΠΊΡ‚ΡƒΡ€Π° синтСзованих сполук Π±ΡƒΠ»Π° ΠΎΠ΄Π½ΠΎΠ·Π½Π°Ρ‡Π½ΠΎ Π΄ΠΎΠ²Π΅Π΄Π΅Π½Π° ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ ПМР-спСктроскопії. Гостра Ρ‚ΠΎΠΊΡΠΈΡ‡Π½Ρ–ΡΡ‚ΡŒ синтСзованих сполук Π±ΡƒΠ»Π° Π²ΠΈΠ²Ρ‡Π΅Π½Π° Π·Π° ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ ΠšΠ΅Ρ€Π±Π΅Ρ€Π°. ВивчСння Π΄Ρ–ΡƒΡ€Π΅Ρ‚ΠΈΡ‡Π½ΠΎΡ— Π΄Ρ–Ρ— ΠΎΡ‚Ρ€ΠΈΠΌΠ°Π½ΠΈΡ… сполук ΠΏΡ€ΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Π·Π° ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ Π‘Π΅Ρ€Ρ…Ρ–Π½Π° Π„. Π‘. Π’ якості Π΅Ρ‚Π°Π»ΠΎΠ½Ρƒ порівняння використовували Π³Ρ–Π΄Ρ€ΠΎΡ…Π»ΠΎΡ€Ρ‚Ρ–Π°Π·ΠΈΠ΄. Висновки. Π‘ΡƒΠ»ΠΈ Ρ€ΠΎΠ·Ρ€ΠΎΠ±Π»Π΅Π½Ρ– прості Ρƒ Π²ΠΈΠΊΠΎΠ½Π°Π½Π½Ρ– ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΈΠΊΠΈ синтСзу 8-Π°ΠΌΡ–Π½ΠΎΠ·Π°ΠΌΡ–Ρ‰Π΅Π½ΠΈΡ… 7-(2-гідрокси-3-ΠΏ-мСтоксифСноксипропіл-1)-3-мСтилксантину. Π‘Ρ‚Ρ€ΡƒΠΊΡ‚ΡƒΡ€Π° синтСзованих сполук Π±ΡƒΠ»Π° Π΄ΠΎΠ²Π΅Π΄Π΅Π½Π° ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ ПМР-спСктроскопії. Π’ΠΈΠ²Ρ‡Π΅Π½Π° гостра Ρ‚ΠΎΠΊΡΠΈΡ‡Π½Ρ–ΡΡ‚ΡŒ Ρ‚Π° Π΄Ρ–ΡƒΡ€Π΅Ρ‚ΠΈΡ‡Π½Π° Π°ΠΊΡ‚ΠΈΠ²Π½Ρ–ΡΡ‚ΡŒ ΠΎΡ‚Ρ€ΠΈΠΌΠ°Π½ΠΈΡ… Ρ€Π΅Ρ‡ΠΎΠ²ΠΈΠ½

    PREVENTION OF ONCOLOGICAL DISEASES AS THE BASIS OF INTERACTION OF ONCOLOGICAL SERVICE WITH PRIMARY LINK OF HEALTH CARE

    Get PDF
    Malignant neoplasms (MN) are the second cause of death for the population of Russia, resulted in 15.5% of all deaths in 2015. Their share in the structure of the male population mortality rate was 16.4%, female β€” 14.4%. Among both sexes, deaths of working age, the proportion of deaths from MN was 16.0%, among women of reproductive age β€” 16.3%. More than half of the working age population of deaths in Russia falls on the disease from the group of preventable death, and a third β€” to preventable causes, depending on the primary and secondary prevention, quality of care, along with a high prevalence of behavioral risk factors (RF), demographic characteristics, marked medical and social reasons for the high mortality rate of the MN: late uptake of the population for health care, lack of alertness in oncology healthcare professionals, patients defects in routing.The leading factor in increasing life expectancy is prevention. Today, prevention is regarded as active method of strengthening and preservation of health, and the currently existing approaches in promoting healthy life mostly only directed at the prevention of behavioral risk factors: tobacco use, poor diet, physical inactivity and harmful use of alcohol. Experts estimate the impact on them will prevent, at least 40% of the cases of MN.In Russia we have a 3-step system of health care. In general preventive health orientation is implemented on the 1st level: in the provision of primary health care. In this regard, particular attention should be paid to the implementation of measures for specific clinical examination of the adult population, which plays an important role in the early detection of both the disease and the risk factors for their development. Properly organized conduct of the clinical examination can provide a substantial, up to 30%, the contribution to the reduction of total mortality, including mortality from MN. The necessity of increasing the role of the oncology service in the organizational and methodological support of the preventive measures implemented by primary health care is performed

    Coupled phase transformations and plastic flows under torsion at high pressure in rotational diamond anvil cell: Effect of contact sliding

    Get PDF
    A three-dimensional large-sliding contact model coupled with strain-induced phase transformations (PTs) and plastic flow in a disk-like sample under torsion at high pressure in rotational diamond anvil cell (RDAC) is formulated and studied. Coulomb and plastic friction are combined and take into account variable parameters due to PT. Results are obtained for weaker, equal-strength, and stronger high pressure phases, and for three values of the kinetic coefficient in a strain-controlled kinetic equation and friction coefficient. All drawbacks typical of problem with cohesion are overcome, including eliminating mesh-dependent shear band and artificial plastic zones. Contact sliding intensifies radial plastic flow, which leads to larger reduction in sample thickness. Larger plastic strain and increased pressure in the central region lead to intensification of PT. However, the effect of the reduction in the friction coefficient on PT kinetics is nonmonotonous. Sliding increases away from the center and with growing rotation and is weakly dependent on the kinetic coefficient. Also, cyclic back and forth torsion is studied and compared to unidirectional torsion. Multiple experimental phenomena, e.g., pressure self-multiplication effect, steps (plateaus) at pressure distribution, flow to the center of a sample, and oscillatory pressure distribution for weaker high-pressure phase, are reproduced and interpreted. Reverse PT in high pressure phase that flowed to the low pressure region is revealed. Possible misinterpretation of experimental PT pressure is found. Obtained results represent essential progress toward understanding of strain-induced PTs under compression and shear in RDAC and may be used for designing experiments for synthesis of new high pressure phases and reduction in PT pressure for known phases, as well as for determination of PT kinetics from experiments

    Stability of the Industrial Reference Standard of Tuberculosis Vaccine (BCG)

    Get PDF
    The industrial reference standard of tuberculosis (BCG) vaccine (IRS), certified and registered by the Federal State Budgetary Institution β€œScientific Centre for Expert Evaluation of Medicinal Products” of the Ministry of Health of the Russian Federation (OSO 42-28-420), is used as a reference product in quality control of tuberculosis vaccines BCG and BCG-M. The IRS is a useful means of quality control of these products, as the stability of its proper ties helps to minimise errors during quality evaluation. The shelf life of the BCG vaccine IRS is not more than 2 years if stored at 2–8 Β°C. It is likely that a vaccine batch could be used as the IRS for a longer period of time. The literature data suggest that the shelf life of a BCG vaccine can be prolonged if it is stored at low temperatures. However, due to significant phenotypic and genotypic differences between BCG sub-strains, the extrapolation of these data to the vaccine produced from the Russian Mycobacterium bovis BCG-I sub-strain requires appropriate testing. The aim of the study was to analyse the possibility of increasing the shelf life of the tuberculosis vaccine IRS by changing the storage temperature. Materials and methods: the effect of low temperatures on the stability of OSO 42-28-420 was studied in commercial batches of tuberculosis vaccine which met all the quality requirements for candidate IRSs. Samples from 6 IRS batches produced from 2014 through 2019 were stored at –(20 Β± 1) Β°Π‘. The stability of their quality characteristics, namely β€œSpecific activity (viability)”, β€œTotal bacterial count”, and β€œDispersibility”, was monitored according to the recommendations of the World Health Organization. The obtained data were evaluated relative to the baseline data obtained during certification of each batch. Results: it was demonstrated that there was more than 95 percent probability that the tested parameters would not differ from the initial data if OSO 42-28-420 samples were stored at a low temperature for 5 years. Conclusions: the results obtained support the prolongation of the OSO 42-28-420 shelf life up to 4 years under the recommended storage conditions at –(20 Β± 1) Β°Π‘

    Preoperative management of ophthalmic patients taking oral anticoagulants

    Get PDF
    Surgical treatment is often accompanied by such complication as bleeding, andΒ ophthalmic surgery is not an exception. The bleeding risk depends on many factors, theΒ most significant are age, arterial hypertension, hepatic and renal impairment, prior stroke or treatment with oral anticoagulants.The aim. To evaluate the structure of patients taking novel oral anticoagulants (NOACs) with anΒ assessment of activated partial thromboplastin time before ophthalmosurgical treatment.Materials and methods. 54Β patients taking oral anticoagulants were included inΒ the study. AΒ retrospective analysis of medical histories of patients who hadΒ surgery for ocular pathology was carried out. The patients were divided into two groups: groupΒ 1 – 28Β patients whose activated partial thromboplastin time (APTT) did notΒ exceed 45Β seconds; groupΒ 2 – 26Β patients with APTT more than 45Β seconds. TheΒ criterion for the numerical expression of APTT is the safety of performing regional anesthesia against the background of taking anticoagulant drugs. Statistical processing wasΒ performed using the Mann – Whitney test (pΒ <Β 0.05).Results. A comparative analysis of the results showed that the patients of theΒ groupΒ 2 had higher rates of APTT. At the same time, they were less likely to have acute cerebrovascular accident (11.5Β % compared to 21Β % of patients in the groupΒ 2) and prior acute myocardial infarction (19Β % and 28Β %, respectively). Among all the patients, women and slightly older patients prevailed.Conclusion. Patients with atrial fibrillation make up the majority of patients undergoing ophthalmosurgical treatment and taking NOACs. Surgical treatment method was phacoemulsification with intraocular lens implantation. Studying APTT before the surgery allowed us to identify aΒ category of patients with high APTT, to prescribe the withdrawal of the drug before the surgery inΒ order to create optimal conditions for surgical treatment

    Specific Aspects of Tuberculin Products Standardisation

    Get PDF
    According to the existing international practice, reference materials, which are used to assess specific activity of purified tuberculin products, are meant to be used for several decades and are therefore characterised by high stability. For instance, PPD-S tuberculin produced in the USA in 1944 has been used ever since as the international reference standard of purified tuberculin and is stored as lyophilisate in ampoules (PPDT) containing 5000 IU each. The Russian PPD-L-2 industry reference standard is made from material produced by the Leningrad Research Institute of Vaccines and Sera in 1973. It has been used for many years to control production batches of PPD-L purified tuberculin because of its high stability that is regularly confirmed in large-scale studies using various experimental models in accordance with the requirements of the World Health Organisation. The aim of the study was to evaluate the long-term stability of the substance of industry reference standard of purified tuberculin (PPD-L-2 IRS) by determining its specific activity relative to the international standard of purified tuberculin, and determine the feasibility of using this substance for the preparation of lyophilised reference product samples. Materials and methods: PPD-L-2 IRS specific activity was determined relative to the PPDT international standard in accordance with the procedure specified in the monograph FS.3.3.1.0023.15 of the State Pharmacopoeia of Russian Federation (14 edition) using guinea pigs vaccinated with various BCG substrains or sensitized by virulent mycobacteria (Β«liveΒ» or Β«inactivatedΒ») in accordance with the recommendations of the WHO (WHO TRS 45, 1987). Results: the analysis of the obtained data showed that there were 3–4-fold differences in PPD-L-2 IRS relative potency depending on the BCG substrain used for guinea pigs vaccination (animal sensitization model). This effect of the titration model manifested itself when comparing specific activity of tuberculins obtained by various methods of tuberculoprotein precipitation (PPD-L-2 and PPDT), i.e. different in antigen composition. The specific activity of the previously established dose of PPD-L-2 IRS was shown to be equivalent to the international reference standard in animals sensitized with mycobacteria tuberculosis. Conclusions: the results of PPD-L-2 IRS specific activity assessment obtained in this study are consistent with the data obtained during development and certification of this reference material in the 1980s and confirm the long-term stability of the intermediate powder product of the Russian reference standard of purified tuberculin. At the same time, the production of a freeze-dried form of the IRS, in addition to being economically feasible, would rule out some potential errors that are inevitable during annual preparation and control of the reference standard dilutions, and would make it possible to spare the substance which would improve prospects for the future long-term use of PPD-L as an industry reference standard

    Π’Π°ΠΊΡ†ΠΈΠ½ΠΎΠΏΡ€ΠΎΡ„ΠΈΠ»Π°ΠΊΡ‚ΠΈΠΊΠ° Ρ‚ΡƒΠ±Π΅Ρ€ΠΊΡƒΠ»Π΅Π·Π°

    Get PDF
    BCG vaccine for tuberculosis was developed nearly 100 years ago and still remains the only medicine for specific immunological prevention of tuberculosis. Despite the fact it has been actively used for a long time in more than 100 countries, the results of vaccination are very contradictory. The protective effect of BCG vaccination is assessed from 0 to 80%, while the efficacy of BCG vaccination in children, especially in infants, is generally recognized. BCG helps to reduce tenfold the number of tuberculous meningitis and disseminated tuberculosis in children. However BCG neither protects the population from mycobacteria infections nor the adults from pulmonary tuberculosis, although it prevents extrapulmonary tuberculosis. For the last 20 years new tuberculosis vaccines have been intensive developed, their efficacy is believed to exceed the efficacy of BCG vaccine, with the minimized adverse reactions. Nevertheless out of more than 200 tuberculosis vaccine candidates only few were allowed for clinical trials. In the upcoming years the humanity can not count upon a medicine that could replace BCG. Therefore the research efforts should be focused on improving BCG vaccine in order to enhance its protective effect and to reduce adverse effects.Бозданная ΠΏΠΎΡ‡Ρ‚ΠΈ 100 Π»Π΅Ρ‚ Π½Π°Π·Π°Π΄ Π²Π°ΠΊΡ†ΠΈΠ½Π° тубСркулСзная Π‘Π¦Π– остаСтся Π΄ΠΎ настоящСго Π²Ρ€Π΅ΠΌΠ΅Π½ΠΈ СдинствСнным ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚ΠΎΠΌ для спСцифичСской иммунологичСской ΠΏΡ€ΠΎΡ„ΠΈΠ»Π°ΠΊΡ‚ΠΈΠΊΠΈ Ρ‚ΡƒΠ±Π΅Ρ€ΠΊΡƒΠ»Π΅Π·Π°. НСсмотря Π½Π° массовоС использованиС Π² Ρ‚Π΅Ρ‡Π΅Π½ΠΈΠ΅ Π΄Π»ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠ³ΠΎ Π²Ρ€Π΅ΠΌΠ΅Π½ΠΈ Π² Π±ΠΎΠ»Π΅Π΅ Ρ‡Π΅ΠΌ Π² 100 странах ΠΌΠΈΡ€Π°, Π΄Π°Π½Π½Ρ‹Π΅ ΠΎ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Π°Ρ… Π²Π°ΠΊΡ†ΠΈΠ½Π°Ρ†ΠΈΠΈ ΠΎΡΡ‚Π°ΡŽΡ‚ΡΡ ΠΎΡ‡Π΅Π½ΡŒ ΠΏΡ€ΠΎΡ‚ΠΈΠ²ΠΎΡ€Π΅Ρ‡ΠΈΠ²Ρ‹ΠΌΠΈ. Π—Π°Ρ‰ΠΈΡ‚Π½Ρ‹ΠΉ эффСкт Π²Π°ΠΊΡ†ΠΈΠ½ Π‘Π¦Π– ΠΎΡ†Π΅Π½ΠΈΠ²Π°ΡŽΡ‚ ΠΎΡ‚ 0 Π΄ΠΎ 80%, ΠΏΡ€ΠΈ этом ΡΡ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ Π²Π°ΠΊΡ†ΠΈΠ½Π°Ρ†ΠΈΠΈ Π‘Π¦Π– Π΄Π΅Ρ‚Π΅ΠΉ, особСнно Ρ€Π°Π½Π½Π΅Π³ΠΎ возраста, ΠΎΠ±Ρ‰Π΅ΠΏΡ€ΠΈΠ·Π½Π°Π½Π½Π°. ΠŸΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ этого ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚Π° способствуСт сниТСнию Π² дСсятки Ρ€Π°Π· числа Ρ‚ΡƒΠ±Π΅Ρ€ΠΊΡƒΠ»Π΅Π·Π½Ρ‹Ρ… ΠΌΠ΅Π½ΠΈΠ½Π³ΠΈΡ‚ΠΎΠ² ΠΈ диссСминированных Ρ„ΠΎΡ€ΠΌ Ρ‚ΡƒΠ±Π΅Ρ€ΠΊΡƒΠ»Π΅Π·Π° Ρƒ Π΄Π΅Ρ‚Π΅ΠΉ. Однако Π‘Π¦Π– Π½Π΅ Π·Π°Ρ‰ΠΈΡ‰Π°Π΅Ρ‚ насСлСниС ΠΎΡ‚ инфицирования микобактСриями, Π° взрослых ΠΎΡ‚ Ρ‚ΡƒΠ±Π΅Ρ€ΠΊΡƒΠ»Π΅Π·Π° Π»Π΅Π³ΠΊΠΈΡ…, хотя ΠΏΡ€Π΅Π΄ΠΎΡ‚Π²Ρ€Π°Ρ‰Π°Π΅Ρ‚ Π²Π½Π΅Π»Π΅Π³ΠΎΡ‡Π½Ρ‹Π΅ Ρ„ΠΎΡ€ΠΌΡ‹ Ρ‚ΡƒΠ±Π΅Ρ€ΠΊΡƒΠ»Π΅Π·Π°. Π’ послСдниС 20 Π»Π΅Ρ‚ вСдутся интСнсивныС Ρ€Π°Π·Ρ€Π°Π±ΠΎΡ‚ΠΊΠΈ Π½ΠΎΠ²Ρ‹Ρ… Ρ‚ΡƒΠ±Π΅Ρ€ΠΊΡƒΠ»Π΅Π·Π½Ρ‹Ρ… Π²Π°ΠΊΡ†ΠΈΠ½, ΡΡ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Ρ…, ΠΊΠ°ΠΊ ΠΏΠΎΠ»Π°Π³Π°ΡŽΡ‚, прСвысят Π²Π°ΠΊΡ†ΠΈΠ½Ρƒ Π‘Π¦Π–, ΠΏΡ€ΠΈ ΠΌΠΈΠ½ΠΈΠΌΠ°Π»ΡŒΠ½Ρ‹Ρ… ΠΏΠΎΠ±ΠΎΡ‡Π½Ρ‹Ρ… рСакциях Π½Π° ΠΈΡ… Π²Π²Π΅Π΄Π΅Π½ΠΈΠ΅. Однако ΠΈΠ· 200 с лишним ΠΊΠ°Π½Π΄ΠΈΠ΄Π°Ρ‚ΠΎΠ² Ρ‚ΡƒΠ±Π΅Ρ€ΠΊΡƒΠ»Π΅Π·Π½Ρ‹Ρ… Π²Π°ΠΊΡ†ΠΈΠ½ Π΄ΠΎ клиничСских исслСдований дошли Π΅Π΄ΠΈΠ½ΠΈΡ†Ρ‹. Π’ блиТайшиС Π³ΠΎΠ΄Ρ‹ чСловСчСство Π½Π΅ ΠΌΠΎΠΆΠ΅Ρ‚ Ρ€Π°ΡΡΡ‡ΠΈΡ‚Ρ‹Π²Π°Ρ‚ΡŒ Π½Π° ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚, ΠΊΠΎΡ‚ΠΎΡ€Ρ‹ΠΉ ΠΌΠΎΠ³ Π±Ρ‹ Π·Π°ΠΌΠ΅Π½ΠΈΡ‚ΡŒ Π²Π°ΠΊΡ†ΠΈΠ½Ρƒ Π‘Π¦Π–. ΠŸΠΎΡΡ‚ΠΎΠΌΡƒ усилия исслСдоватСлСй Π΄ΠΎΠ»ΠΆΠ½Ρ‹ Π±Ρ‹Ρ‚ΡŒ Π½Π°ΠΏΡ€Π°Π²Π»Π΅Π½Ρ‹ Π½Π° ΡƒΡΠΎΠ²Π΅Ρ€ΡˆΠ΅Π½ΡΡ‚Π²ΠΎΠ²Π°Π½ΠΈΠ΅ Π²Π°ΠΊΡ†ΠΈΠ½Ρ‹ Π‘Π¦Π– с Ρ†Π΅Π»ΡŒΡŽ ΠΏΠΎΠ²Ρ‹ΡˆΠ΅Π½ΠΈΡ Π΅Π΅ Π·Π°Ρ‰ΠΈΡ‚Π½ΠΎΠ³ΠΎ эффСкта ΠΈ сниТСния ΠΏΠΎΠ±ΠΎΡ‡Π½ΠΎΠ³ΠΎ дСйствия

    New advances in Raman study of polyvinylchloride structure

    Get PDF
    In this work we investigated Raman spectra of a number of industrial grades of polyvinylchloride powder and films, prepared from solutions in tetrahydrofuran and acetophenone. The number and spectral characteristics of the Raman lines in the spectral regions of the C-Cl stretching vibrations and in the region of the C-H and CH2 stretching vibrations were evaluated

    БонографичСскиС ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»ΠΈ Π΄ΠΈΠ°Ρ„Ρ€Π°Π³ΠΌΡ‹ ΠΈ ΠΈΡ… коррСляции со спиромСтричСскими Π΄Π°Π½Π½Ρ‹ΠΌΠΈ Ρƒ Π·Π΄ΠΎΡ€ΠΎΠ²Ρ‹Ρ… Π»ΠΈΡ†: проспСктивноС клиничСскоС исслСдованиС

    Get PDF
    Π¦Π•Π›Π¬ Π˜Π‘Π‘Π›Π•Π”ΠžΠ’ΠΠΠ˜Π―: Π’Ρ‹ΡΠ²ΠΈΡ‚ΡŒ коррСляционныС взаимосвязи сонографичСских ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»Π΅ΠΉ функционирования Π΄ΠΈΠ°Ρ„Ρ€Π°Π³ΠΌΡ‹ со спиромСтричСскими Π΄Π°Π½Π½Ρ‹ΠΌΠΈ ΡƒΒ Π·Π΄ΠΎΡ€ΠΎΠ²Ρ‹Ρ… Π»ΠΈΡ†. ΠœΠΠ’Π•Π Π˜ΠΠ›Π« И ΠœΠ•Π’ΠžΠ”Π«: На Π±Π°Π·Π΅ Π€Π“Π‘Π£ «НМИЦ ΠΈΠΌ.Β Π’.А. Алмазова» ΡƒΒ 50Β Π·Π΄ΠΎΡ€ΠΎΠ²Ρ‹Ρ… Π΄ΠΎΠ±Ρ€ΠΎΠ²ΠΎΠ»ΡŒΡ†Π΅Π² (ΠΆΠ΅Π½Ρ‰ΠΈΠ½Β β€” 30) ΠΎΡ†Π΅Π½ΠΈΠ»ΠΈ структурноС (Ρ‚ΠΎΠ»Ρ‰ΠΈΠ½Ρƒ) ΠΈΒ Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΎΠ½Π°Π»ΡŒΠ½ΠΎΠ΅ (индСкс утолщСния ΠΈΒ ΡΠΊΡΠΊΡƒΡ€ΡΠΈΡŽ) состояниС Π΄ΠΈΠ°Ρ„Ρ€Π°Π³ΠΌΡ‹ ΡΒ ΠΏΠΎΠΌΠΎΡ‰ΡŒΡŽ ΡƒΠ»ΡŒΡ‚Ρ€Π°Π·Π²ΡƒΠΊΠΎΠ²ΠΎΠ³ΠΎ исслСдования, Π°Β Ρ‚Π°ΠΊΠΆΠ΅ спиромСтричСскиС характСристики Π°ΠΏΠΏΠ°Ρ€Π°Ρ‚Π° внСшнСго дыхания ΡΒ ΠΏΠΎΠΌΠΎΡ‰ΡŒΡŽ Π°ΠΏΠΏΠ°Ρ€Π°Ρ‚Π° искусствСнной вСнтиляции Π»Π΅Π³ΠΊΠΈΡ…. ПослС Ρ‡Π΅Π³ΠΎ ΠΏΡ€ΠΎΠ²Π΅Π»ΠΈ ΡΡ‚Π°Ρ‚ΠΈΡΡ‚ΠΈΡ‡Π΅ΡΠΊΡƒΡŽ ΠΎΠ±Ρ€Π°Π±ΠΎΡ‚ΠΊΡƒ и коррСляционный Π°Π½Π°Π»ΠΈΠ·. РЕЗУЛЬВАВЫ: Π’ΠΎΠ»Ρ‰ΠΈΠ½Ρƒ Π΄ΠΈΠ°Ρ„Ρ€Π°Π³ΠΌΡ‹ (слСва и справа) ΠΈΒ Π΅Π΅ ΡΠΊΡΠΊΡƒΡ€ΡΠΈΡŽ (справа) ΡƒΠ΄Π°Π»ΠΎΡΡŒ ΠΎΡ†Π΅Π½ΠΈΡ‚ΡŒ у всСх испытуСмых; ΡΠΊΡΠΊΡƒΡ€ΡΠΈΡŽ Π΄ΠΈΠ°Ρ„Ρ€Π°Π³ΠΌΡ‹ слСва — Ρ‚ΠΎΠ»ΡŒΠΊΠΎ ΡƒΒ 20Β % испытуСмых. Π‘ΠΏΠΈΡ€ΠΎΠΌΠ΅Ρ‚Ρ€ΠΈΡŽ Π²Ρ‹ΠΏΠΎΠ»Π½ΠΈΠ»ΠΈ у всСх испытуСмых. ΠŸΠΎΠ»ΡƒΡ‡Π΅Π½Π½Ρ‹Π΅ Π΄Π°Π½Π½Ρ‹Π΅ ΡΠΎΠ³Π»Π°ΡΡƒΡŽΡ‚ΡΡ с литСратурными. В частности, ΡƒΠ»ΡŒΡ‚Ρ€Π°Π·Π²ΡƒΠΊΠΎΠ²Ρ‹Π΅ и спиромСтричСскиС ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»ΠΈ для Π·Π΄ΠΎΡ€ΠΎΠ²Ρ‹Ρ… Π»ΠΈΡ† Π½Π°Ρ…ΠΎΠ΄ΠΈΠ»ΠΈΡΡŒ Π²Β Ρ€Π°ΠΌΠΊΠ°Ρ… Ρ€Π΅Ρ„Π΅Ρ€Π΅Π½Ρ‚Π½Ρ‹Ρ… Π·Π½Π°Ρ‡Π΅Π½ΠΈΠΉ. Π‘ΠΈΠ»Π° инспираторных ΠΌΡ‹ΡˆΡ† Ρ‚Π°ΠΊΠΆΠ΅ оказалась сопоставимой с литСратурными Π΄Π°Π½Π½Ρ‹ΠΌΠΈ. ΠšΠΎΡ€Ρ€Π΅Π»ΡΡ†ΠΈΠΎΠ½Π½Ρ‹ΠΉ Π°Π½Π°Π»ΠΈΠ· Π½Π΅ выявил статистичСски Π·Π½Π°Ρ‡ΠΈΠΌΡ‹Ρ… взаимосвязСй ΠΌΠ΅ΠΆΠ΄Ρƒ ΠΈΠ·ΡƒΡ‡Π΅Π½Π½Ρ‹ΠΌΠΈ ΡƒΠ»ΡŒΡ‚Ρ€Π°Π·Π²ΡƒΠΊΠΎΠ²Ρ‹ΠΌΠΈ и спиромСтричСскими ΠΏΠ°Ρ€Π°ΠΌΠ΅Ρ‚Ρ€Π°ΠΌΠΈ. Π’Π°ΠΊΠΆΠ΅ Π½Π΅ Π±Ρ‹Π»ΠΎ выявлСно взаимосвязи ΠΌΠ΅ΠΆΠ΄Ρƒ возрастом ΠΈΒ ΡƒΠ»ΡŒΡ‚Ρ€Π°Π·Π²ΡƒΠΊΠΎΠ²Ρ‹ΠΌΠΈ показатСлями Π΄ΠΈΠ°Ρ„Ρ€Π°Π³ΠΌΡ‹. НайдСны слабыС статистичСски Π·Π½Π°Ρ‡ΠΈΠΌΡ‹Π΅ связи ΠΌΠ΅ΠΆΠ΄Ρƒ структурно-Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΎΠ½Π°Π»ΡŒΠ½Ρ‹ΠΌ состояниСм Π΄ΠΈΠ°Ρ„Ρ€Π°Π³ΠΌΡ‹ и антропомСтричСскими характСристиками обслСдованных: массой Ρ‚Π΅Π»Π° и индСксом массы Ρ‚Π΅Π»Π°. Π’Π«Π’ΠžΠ”Π«: Π£Π»ΡŒΡ‚Ρ€Π°Π·Π²ΡƒΠΊΠΎΠ²Ρ‹Π΅ ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»ΠΈ Ρ€Π°Π±ΠΎΡ‚Ρ‹ Π΄ΠΈΠ°Ρ„Ρ€Π°Π³ΠΌΡ‹ Π½Π΅ ΠΊΠΎΡ€Ρ€Π΅Π»ΠΈΡ€ΡƒΡŽΡ‚ ΠΈΠ»ΠΈ ΠΏΠ»ΠΎΡ…ΠΎ ΠΊΠΎΡ€Ρ€Π΅Π»ΠΈΡ€ΡƒΡŽΡ‚ со спиромСтричСскими. Π£Β Π·Π΄ΠΎΡ€ΠΎΠ²Ρ‹Ρ… Π»ΠΈΡ† Π½Π΅Ρ‚ оснований ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΠΎΠ²Π°Ρ‚ΡŒ ΡƒΠ»ΡŒΡ‚Ρ€Π°Π·Π²ΡƒΠΊΠΎΠ²ΠΎΠ΅ исслСдованиС Π΄ΠΈΠ°Ρ„Ρ€Π°Π³ΠΌΡ‹, Ρ‚Π°ΠΊ ΠΊΠ°ΠΊ ΠΎΠ½ΠΎ практичСски Π½Π΅ Π΄Π°Π΅Ρ‚ Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΈΠ½Ρ„ΠΎΡ€ΠΌΠ°Ρ†ΠΈΠΈ о состоянии Π°ΠΏΠΏΠ°Ρ€Π°Ρ‚Π° внСшнСго дыхания
    • …
    corecore